Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617

BACKGROUND: Lutetium-177-prostate-specific membrane antigen- 617 (Lu-PSMA) is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC). However, treatment responses are heterogeneous despite stringent positron emission tomography (PET)-based imaging selection criteria. Molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Crumbaker, Megan, Goldstein, Leonard D., Murray, David H., Tao, Jiang, Pathmanandavel, Sarennya, Boulter, Nicky, Ratnayake, Lalith, Joshua, Anthony M., Kummerfeld, Sarah, Emmett, Louise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658415/
https://www.ncbi.nlm.nih.gov/pubmed/38020530
http://dx.doi.org/10.1016/j.euros.2023.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658415/
https://www.ncbi.nlm.nih.gov/pubmed/38020530
http://dx.doi.org/10.1016/j.euros.2023.08.007

Ejemplares similares